Supplementary methods

Supplementary Table 1. Blood collection for correlative studies

Supplementary Table 2. Antibodies used in this study

Supplementary Table 3. Liver-related adverse events

Supplementary Table 4. Summary of worst-grade hepatotoxicity, gastrointestinal toxicity, and all adverse events

Supplementary Table 5. Tumor subtyping based on gene expression pattern

Supplementary Figure 1. Consort diagram

Supplementary Figure 2. Multiplex analysis of cytokines in patients with gastrointestinal toxicity. Comparison of pre-treatment levels and levels at the onset of gastrointestinal toxicity (n=17)

Supplementary Figure 3. Flow cytometric analysis of regulatory T cells. Comparison of pre-treatment levels and levels at onset of gastrointestinal toxicity (n=17)

Supplementary Figure 4. Genotyping of HLA and ABCG2 from DNA extracted from PBMCs (n=17)